Genzyme Corporation (NASDAQ: GENZ) catches a bullish trend
Genzyme Corporation is ready for the major buying
In brief: Genzyme Corporation (NASDAQ: GENZ) is increasing in price. Genzyme began discussions with Sanofi about selling the business.Genzyme Corporation (NASDAQ: GENZ) stayed in the green area at around 70.36 yesterday. Genzyme Co shares gained +0.80 (1.15%). Pre-market today: 71.88 +1.52 (2.16%). The good news are supporting the bulls.
The world’s largest producer of drugs for the treatment of genetic diseases, Genzyme began talks with Sanofi-Aventis to sell the business. It is reported that the French pharmaceutical company Sanofi made an offer the board Genzyme to buy the company at a price of $ 67 to $ 70 per share. The shareholders of American companies are willing to receive an offer to buy businesses at a price of $ 80 per share.
Anrey Torbinski2010-08-03 11:02, Economics.
News on: genetic diseases, Genzyme Co, Genzyme Corporation, pharmaceutical, producer, Sanofi, Sanofi-Aventis, stock markets, technologies, treatment of genetic diseases, USD